Pureos Bioventures
Venture capitalPfäffikon · Seed–Series C · 9 people tracked
Investment thesis
Pureos Bioventures provides venture capital to private companies developing innovative therapeutics for severe diseases and conditions. The firm emphasizes the next generation of biological drugs and novel drug formats, aiming to improve patients' lives by advancing new treatments. It backs strong founding teams with development programs that make a meaningful difference for patients, and its portfolio spans oncology, fibrosis, immune-mediated inflammatory diseases, neurological disorders, ophthalmology, cardiovascular disease, vaccines and rare diseases. The team combines career venture capitalists, biotech founders, former pharma and biotech executives, research scientists, medical doctors and experienced drug developers.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from public directories
Founder mafia
4 people who came through Pureos Bioventures went on to found or lead other companies.
What they invest in
from 16 of 22 portfolio companiesBiotech ×16Healthtech ×11Medical Devices ×8AI & Machine Learning ×4Deep Tech ×3
HQs:Switzerland×4France×1Netherlands×1Sweden×1United States×1
Investments · 22 tracked
founders shown can be your intro pathAraris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy.
BiotechMedical DevicesBasel, CH
Dragan Grabulovski(Co-founder and CEO)inPhilipp Spycher(Co-founder and Chief Scientific Officer)Isabella Attinger-Toller(Co-founder)
Co-investorsredalpineSamsung VenturesVI Partnersb2ventureKinled Holding
PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness.
BiotechHealthtechMedical Devices
Co-investors+ND Capital
Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases.
BiotechDeep TechHealthtechParis, FR
Co-investorsAdvent Life SciencesBioqube VenturesBpifranceAdBio partners
Acrivon develops targeted precision oncology therapies matched to patients through its proteomics-based patient selection method, aiming to treat common solid cancers.
AI & Machine LearningBiotechHealthtechBoston, US
erick gamelinin
Co-investorsNew Enterprise Associates (NEA)RA Capital
Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology.
BiotechHealthtechMedical Devices
Jack Elands(Founder & CEO)inXavier Preville(Co-founder, VP & Head of Research & Preclinical Development)inJan H.M. Schellens(Chief Medical Officer)inThierry Menguy(VP & Head of CMC Operations)inJaime Arango(Chief Financial Officer)inPaul Jackson(Chief Operating Officer)in
Co-investorsaMoonRA CapitalBpifranceAndera PartnersAngelini VenturesKurma Partners+1 more
Alentis Therapeutics is a clinical-stage biotech company developing anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies to treat cancer and reverse organ fibrosis.
BiotechHealthtech
Co-investorsAvego BioScience CapitalBioMedPartnersCatalio Capital Management, LPFrazier Life SciencesJeito CapitalLongitude Capital+3 more
AnaCardio is a clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, including its GOAL-HF1 program for patients with Heart Failure and Reduced Ejection Fraction (HFrEF).
BiotechMedical DevicesStockholm, SE
Co-investors3B Future Health FundIndustrifondenNovo HoldingsSound Bioventures
Basel-area incubator and accelerator helping launch biotech companies in Switzerland.
Seattle and Singapore-based biotech developing next-generation multi-payload antibody-drug conjugates for cancer treatment.
Co-investorsClavystBioFrazier Life SciencesJeito CapitalNorwest Venture Partners
Citryll is a biotech company developing CIT-013, a first-in-class monoclonal antibody that targets Extracellular Traps (ETs) to treat immune-mediated inflammatory diseases, with a focus on rheumatoid arthritis and hidradenitis suppurativa.
BiotechHealthtechMedical DevicesOss, NL
Co-investorsBOMCurie CapitalNovartis Venture FundBioGeneration VenturesForbion
French biotech developing gene therapies for neurological diseases; acquired by uniQure in 2021.
Engimmune Therapeutics develops off-the-shelf soluble T-cell receptor (TCR) drugs to treat solid tumor cancers, using AI-guided protein engineering platforms to identify and engineer multi-specific TCRs.
AI & Machine LearningBiotechDeep Tech
French startup developing novel treatments for respiratory and inflammatory diseases.
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)Konrad Paszkiewicz(Chief Technology Officer)Kwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)
Co-investorsAltium CapitalClavystBioDecheng CapitalDroia VenturesFrazier Life SciencesKiwoom Investment+2 more
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.
BiotechHealthtech
Co-investorsAndera PartnersKurma PartnersPfizer Venture InvestmentsAgent CapitalGimv
Boston-based preclinical biotech developing antibody therapeutics targeting fibrotic mediators and myofibroblasts.
Memo Therapeutics AG is a late-stage biotech company developing therapeutic antibodies for patients with viral infections and cancer.
BiotechMedical Devices
Co-investorsAdjuvant CapitalFresenius Medical Care VenturesKurma PartnersVerve VenturesYsios Capitalredalpine
MinervaX is a clinical-stage biotech company developing a prophylactic vaccine against Group B Streptococcus, with a lead candidate (AlpN GBS) in clinical trials for use in pregnancy and older adults.
BiotechHealthtech
Co-investorsAdjuvant CapitalIndustrifondenLU InnovationOrbiMedSanofi VenturesSunstone Capital+2 more
NovaGo Therapeutics is a Swiss biotech company developing human therapeutic antibodies that block the Nogo-A receptor to stimulate nerve growth and regeneration after spinal cord injury.
BiotechMedical Devices
Clinical-stage company developing novel therapies for orphan renal diseases.
Co-investorsBain Capital Life SciencesSR One Capital Management
Tavo Biotherapeutics develops novel treatments for glaucoma and retinal diseases, focusing on disease-modifying therapies that target the root biological mechanisms of vision loss.
BiotechHealthtechMedical Devices
Vico Therapeutics is a genetic medicine company developing antisense oligonucleotide (ASO) therapies that target the CAG repeat expansion mutation underlying polyglutamine diseases such as Huntington's disease and spinocerebellar ataxias.
AI & Machine LearningBiotechHealthtech
Co-investorsDroia VenturesKurma PartnersSeroba Life SciencesEQT Life SciencesEurazeoIdinvest Partners
Exits · 2
IPOs and acquisitions across the tracked portfolioImcheckacq. by ClementiaMemo Therapeuticsacq. by Clementia
Portfolio news
latest coverage across their companiesMemo Therapeutics · investing.com · Jul 22, 2026
Alentis · biopharminternational.com · Jun 29, 2026
Hummingbird Bioscience · fiercebiotech.com · Dec 19, 2025
Adcytherix · pharmaceutical-technology.com · Oct 17, 2025
Frequently asked questions
- How many investments has Pureos Bioventures made?
- Pureos Bioventures has 20 tracked investments, 2 of which have exited via acquisition or IPO.
- What stage does Pureos Bioventures invest at?
- Pureos Bioventures invests at the Seed, Series A, Series B, Series C stages.
- What sectors does Pureos Bioventures focus on?
- Pureos Bioventures focuses on Biotech, Healthtech, Medical Devices.
- Where is Pureos Bioventures located?
- Pureos Bioventures is headquartered in Pfäffikon, CH.
- Who does Pureos Bioventures co-invest with?
- Pureos Bioventures most often shares deals with Frazier Life Sciences, Kurma Partners, RA Capital, among 40 tracked co-investors.
Images
Co-investors · 11
Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.
Andera Partners is an asset management firm specializing in private equity that partners with companies and their management to support sustainable growth. It has backed 377 companies over more than 20 years.
Adjuvant Capital is a venture capital firm that finances life science technologies addressing high-burden public health challenges, aiming to deliver both social and financial returns.
Norwest Venture Partners is an investment firm whose growth equity team backs private, profitable, fast-growing companies, providing capital and hands-on support through its 'invited guest' approach.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
Advent Life Sciences is a trans-Atlantic venture capital firm investing in early and mid-stage life sciences companies across the UK, Europe and the USA.
Earlybird Venture Capital is a European venture capital investor that backs early-stage technology founders with capital, strategic support, and access to an international network.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
HealthCap is a life science venture capital investor and company creator that backs innovative healthcare ideas, people, and companies aiming to impact healthcare and society.
4BIO Capital is a London-based venture capital firm investing in life sciences, with a focus on advanced therapies that address high unmet medical and social needs.
Firms observed investing alongside Pureos Bioventures, from public investor directories. Shared companies are the overlap with Pureos Bioventures's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.